EGFRt is a safety tag on the CAR T cells; the anti-CD33 CAR does not target EGFR. Only if an anti-EGFR antibody (e.g., cetuximab) is administered would EGFRt+ CAR T cells be eliminated via antibody-mediated cytotoxicity, not by the CAR T cells themselves.